ArticleThorax2003
Increased interleukin-13 expression in patients with sarcoidosis.
Article in Thorax, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 75 citations in OpenAlex.
- Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.Nature communications · 2022Trial
- Fibrotic Pulmonary Sarcoidosis-From Pathogenesis to Management.Journal of clinical medicine · 2025Review
- Chronic Sarcoidosis: Diagnostic Difficulties and Search for New Criteria of Inflammatory Activity (A Case Report and Literature Review).Journal of clinical medicine · 2024Review
- Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.The Journal of clinical investigation · 2024Review
- Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?Frontiers in pharmacology · 2024Review
- Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis.International journal of molecular sciences · 2023Review
- Sarcoidosis and Autoimmune Inflammatory Syndrome Induced by Adjuvants.Life (Basel, Switzerland) · 2023Review
- Autoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program.Rheumatology advances in practice · 2023Article
- Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients.Frontiers in medicine · 2023Review
- Immune mechanisms in fibrotic pulmonary sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.American journal of clinical dermatology · 2022Review
- Sarcoidosis: Progression to the chronic stage and pathogenic based treatment (narrative review).Frontiers in medicine · 2022Review
- Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation.Advances in experimental medicine and biology · 2022Article
- Key Players and Biomarkers of the Adaptive Immune System in the Pathogenesis of Sarcoidosis.International journal of molecular sciences · 2020Review
- Peroxisome Proliferator-activated Receptor-γ Deficiency Exacerbates Fibrotic Response to Mycobacteria Peptide in Murine Sarcoidosis Model.American journal of respiratory cell and molecular biology · 2019Article
- Macrophage Polarization in Sarcoidosis: An Unexpected Accomplice?American journal of respiratory cell and molecular biology · 2019Article
- IL-13-regulated Macrophage Polarization during Granuloma Formation in an In Vitro Human Sarcoidosis Model.American journal of respiratory cell and molecular biology · 2019Article
- Role of interleukin 4 and its receptor in clinical presentation of chronic extrinsic allergic alveolitis: a pilot study.Multidisciplinary respiratory medicine · 2013Article
- Sarcoidosis: Immunopathogenesis and Immunological Markers.International journal of chronic diseases · 2013Review
- The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.Translational research : the journal of laboratory and clinical medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is a systemic granulomatous disorder of unknown origin. Lymphocytic inflammation is dominated by expression of Th1 type cytokines such as tumour necrosis factor alpha (TNFalpha). Interleukin 13 (IL-13) is a Th2 cytokine which is expressed by CD4+ T cells and has been shown to suppress TNFalpha in human blood monocytes. The role of IL-13 as a possible anti-inflammatory cytokine in sarcoidosis was investigated.
methodsmRNA expression of IL-13, IL-4, IL-10, and TNFalpha in bronchoalveolar lavage (BAL) fluid cells and peripheral mononuclear blood cells (PBM) of 18 patients with sarcoidosis and nine healthy controls was assessed using RT-PCR. In addition, IL-13 protein levels in BAL cell culture supernatants from 12 patients and all controls were measured and immunocytochemistry of IL-13 protein was performed in BAL fluid cells of eight patients. TNFalpha concentrations were measured with and without stimulation with recombinant human (rh) IL-13, rhIL-10, and lipopolysaccharide (LPS).
resultsIL-13 mRNA expression was significantly increased in BAL cells and PBM of patients compared with controls (p<0.05). No significant difference was found in IL-4 mRNA or IL-10 mRNA expression in BAL fluid cells or PBM between the two groups. TNFalpha mRNA expression was significantly higher in BAL fluid cells of patients than controls (p<0.05). IL-13 protein levels in BAL cell culture supernatants were slightly raised in half the patients investigated but in only two controls. Immunocytochemistry detected IL-13 protein in alveolar macrophages of patients. IL-13 led to decreased TNFalpha concentrations (p<0.05).
conclusionsIL-13 expression is increased in BAL cells and PBM in sarcoidosis and IL-13 is secreted from BAL cells. Alveolar macrophages may be the cellular source. These data suggest that IL-13 might have an anti-inflammatory effect by acting on TNFalpha.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.